Verici Dx PLC Notice of Results and Business Update
11 Julho 2024 - 10:00AM
RNS Regulatory News
RNS Number : 0926W
Verici Dx PLC
11 July 2024
Verici Dx plc
("Verici Dx" or the
"Company")
Notice of Results and Business
Update
Verici Dx plc (AIM: VRCI), a
developer of advanced clinical diagnostics for organ
transplant, announces that it will report
its interim results for the six months to 30 June 2024, together
with a business update, on 15 July 2024.
Investor roadshow and briefings
Sara Barrington, Chief Executive
Officer, and David Anderson, Chief Financial Officer, will provide
a live online presentation via the Investor Meet Company platform
on Tuesday 16th July 2024 at 16:30 BST. This presentation is open
to all existing and potential shareholders. Questions can be
submitted pre-event via the Investor Meet Company dashboard up
until 9.00 am BST the day before the meeting or during the live
presentation. Investors can sign up to Investor Meet Company for
free and add to meet VERICI DX PLC via:
https://www.investormeetcompany.com/verici-dx-plc/register-investor
The Company will also be presenting
in person at The Novotel, London on Wednesday 17 July 2024 at 18.00
BST as part of the regular series of "Shares" investor events
hosted by AJ Bell. Existing shareholders and potential investors
can register to attend this live evening event for free at:
Shares Magazine - Events
Enquiries:
Verici Dx
|
www.vericidx.com
|
Sara Barrington, CEO
|
investors@vericidx.com
|
Julian Baines, Chairman
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
Phil Davies / Sam Butcher
|
|
About Verici Dx plc
www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORRBMBTMTABBII
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024